In compliance with current regulations, let us know which audience you belong to:
Bologna, Italy / Reykjavik, Iceland — November 30th 2022
Espansione Group, the leading medical device company offering screening and treatment solutions for ocular conditions, and Reykjavik University (Iceland) are thrilled to announce the signing of a partnership between the univeristy’s Heilbrigdistaeknisetur (Institute of Biomedical and Neural Engineering) from Reykjavik University, Iceland.
We take the chance of this announcement to thank the Head of the Institute, Professor Paolo Gargiulo, for participating in this scientific cooperation. We also thank Dr. Sònia Travé Huarte, optometrist and researcher specializing in dry eye diagnostic and treatments, anterior ocular surface disease management, specialty contact lenses, and Meibomian gland dysfunction (MGD), to be part of the project as specialist in the field.
The main objectives of the collaboration are the following:
The institute will recruit 100 individuals and will assess the status of the Meibomian glands on the lower lid, and will monitor the subject for four weeks of treatment.
As far as both parties are aware at the time of publishing, the study will evaluate for the first time in scientific literature the immediate effect of a Light Modulation® Low-level Light Therapy (LM® LLLT) treatment.
> ON REYKJAVIK UNIVERSITY
The role of Reykjavik University (RU) is to create and dissemi- nate knowledge in order to enhance the competitiveness and quality of life for individuals and society, guided by good ethics, sustainability, and responsibility.
The Institute of Biomedical and Neural Engineering (Heilbrigdistaeknisetur) is an internationally recognized research center established by the University Hospital Landspitali and Reykjavik University with the aim to improve healthcare processes and translational research in biomedicine.
Visit the university's website at en.ru.is
> ON ESPANSIONE GROUP
Espansione Group is an established player in the MedTech industry focusing on ophthalmic and dermatological solutions to treat a number of conditions via patented, certified, light-based technologies such as Light Modulation® Low-level Light Therapy (LM® LLLT), it’s signature photobiomodulation (PMB) technology, and Optimal Power Energy® Intense Pulsed Light (OPE® IPL).
Since 1981, Espansione Group has delivered the highest standard in the industry—pushed on by expert craftsmanship and family-owned values coupled with a global mindset and aspiration. Every day, the company invests heavily in researching and developing the Espansione Ecosystem of technologies and solutions to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies.
With more than 6 international patents and over 1,100 solutions installed worldwide, Espansione Group's technologies are responsible for the betterment of thousands of people worldwide, with over 400,000 yearly treatments being carried out each year with its solutions.
Present in over 50 countires, Espansione Group's is bound to hold strong on its strong growth path in the years to come, relentlessly focusing its efforts on research, development and customer excellence.
Visit the company’s website at espansionegroup.it
Source: Espansione Group
© 2022 Espansione Group, All Rights Reserved
Posted on November 30th, 2022 in Newsroom